source
- Multidisciplinary quality program shown to cut side effects of androgen deprivation therapy in prostate cancerDr Hafron discussed a recent study that evaluated a multidisciplinary quality initiative aimed at reducing adverse events linked to androgen deprivation therapy for prostate cancer. The program co…
- FDA approves trastuzumab deruxtecan for early-stage HER2-positive breast cancerThe U.S. Food and Drug Administration has granted approval for trastuzumab deruxtecan (T‑DXd) as a treatment option in both the adjuvant and neoadjuvant settings for certain patients with early-sta…onclive · 5mo agoApprovalPositive